Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2678466 | 1.00 | EPHX2 (0.47) | EPHX2GAAHTTP2RX7CYP2C9 | |
| SCHEMBL2678190 | 0.90 | EPHX2 (0.56) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2678193 | 0.90 | EPHX2 (0.56) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2678302 | 0.87 | EPHX2 (0.49) | EPHX2GAAHTTP2RX7CYP2C9 | |
| SCHEMBL2678296 | 0.87 | EPHX2 (0.49) | EPHX2GAAHTTP2RX7CYP2C9 | |
| SCHEMBL2241438 | 0.85 | EPHX2 (0.54) | EPHX2GAAHTTP2RX7CYP2C9 | |
| SCHEMBL2241434 | 0.85 | EPHX2 (0.54) | EPHX2GAAHTTP2RX7CYP2C9 | |
| SCHEMBL2677015 | 0.83 | EPHX2 (0.52) | EPHX2GAAHTTP2RX7CYP2C9 | |
| SCHEMBL2678425 | 0.83 | EPHX2 (0.52) | EPHX2GAAHTTP2RX7CYP2C9 | |
| SCHEMBL2677018 | 0.83 | EPHX2 (0.52) | EPHX2GAAHTTP2RX7CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173805-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2012-05-08 | — | — | US | claimed |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | claimed |
| EP-2214487-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-08-11 | — | — | EP | claimed |
| WO-2009049157-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | claimed |
| US-8212032-B2 | sEH inhibitors and their use | GLAXOSMITHKLINE LLC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8173805-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100249137-A1 | Novel sEH Inhibitors and Their Use | GlaxoSmithKline, LLC | 2010-09-30 | — | — | US | disclosed |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249137-A1 | Novel sEH Inhibitors and Their Use | NCEH1, CTH, EPHX1 | EPHX2 8/4885GAA 1067/4885HTT 3854/4885 |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | NCEH1, EPHX1, FAH | EPHX2 4/4885GAA 453/4885HTT 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.